KoreaBiotech & Genomic Medicine▲
AI in Pathology Market to Surpass $633.69 Million by 2031
The global AI in pathology market is projected to grow from USD 145.39 million in 2025 to USD 633.69 million by 2031, at a compound annual growth rate of 28.16 percent from 2026 to 2031. Software led the market with a 50.33 percent share in 2025, while services are expected to grow at a 29.20 percent CAGR through 2031. North America held a 50.13 percent market share in 2025, and Asia-Pacific is forecast to achieve the highest CAGR of 31.24 percent through 2031. Key regulatory milestones include PathAI's AISight Dx becoming the first FDA-cleared system with a Predetermined Change Control Plan in June 2025, and Roche's VENTANA TROP2 RxDx Device receiving FDA Breakthrough Device Designation. The report covers companies such as Aiforia Technologies, Ibex Medical Analytics, Lunit, Paige, and Philips Digital & Computational Pathology.
About megatrends
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
Artificial Intelligence › AI Applications & Copilots ▲Demand
ROP.SW · Regulation · Positive Roche's VENTANA TROP2 RxDx Device received FDA Breakthrough Device Designation, a regulatory milestone.
PathAI, Inc. · Regulation · Positive PathAI's AISight Dx received first FDA clearance with Predetermined Change Control Plan, a key regulatory milestone.
328130.KQ · Demand · Positive Lunit is a key player in the rapidly growing AI pathology market, projected to grow at 28.16% CAGR.
Aiforia Technologies Oyj · Demand · Positive Aiforia Technologies is a key player in the rapidly growing AI pathology market, projected to grow at 28.16% CAGR.
Ibex Medical Analytics · Demand · Positive Ibex Medical Analytics is a key player in the rapidly growing AI pathology market, projected to grow at 28.16% CAGR.